PEP-1

Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company, is pleased to announce that the US Patent and Trademark Office has granted the first patent regarding Aptorum’s SACT-1 repurposed drug for the treatment of various cancers including but not limited to neuroblastoma (US Patent 11,166,962 B2). The SACT-1 invention provides a composition and method for treating or preventing the growth of cancerous tumors and/ or delaying the onset of cancer from tumor-initiating cells. The composition is administered alone or in combination with one or more chemotherapeutic agents, biological agents, and/or anticancer agents by various routes of administration and dosage forms. Mr Darren Lui, President and Executive Director of Aptorum Group says, “In addition to our previous announcement of the completion of our Phase 1 clinical trial of SACT-1 on January 10, 2022, we are pleased to have received the granted patent from the USPTO on our drug candidate. As IP protection is critically important for protecting our investment in developing repurposed drugs, the granted patent will further support our ongoing development effort of SACT-1 as a potentially effective treatment of neuroblastoma and other cancer types. We will be actively seeking further IP protection on our SACT-1 repurposed drug via patent applications in major jurisdictions and the embarking of the exciting Phase Ib/2a clinical trials for SACT-1, subject to IND clearance in 2022.” About SACT-1 SACT-1 is an orally administered repurposed small molecule drug to target neuroblastoma. SACT-1’s mechanism has been investigated in our preclinical studies to enhance tumor cell death and suppress MYCN expression (a common clinical diagnosis in high-risk or relapsed neuroblastoma patients where an amplification of MYCN is usually observed). SACT-1 is designed to be used especially in combination with standard-of-care chemotherapy. About Aptorum Group Limited Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) is a clinical stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The pipeline of Aptorum is also enriched through (i) the establishment of drug discovery platforms that enable the discovery of new therapeutics assets through, e.g. systematic screening of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases; and (ii) the co-development of a novel molecular-based rapid pathogen identification and detection diagnostics technology with Accelerate Technologies Pte Ltd, commercialization arm of the Singapore’s Agency for Science, Technology and Research.